8 Results for "

Ipatasertib

" in MedChemExpress (MCE) Product Catalog:
Products (8)

8 Results for "Ipatasertib" in MCE Product Catalog:

63
63 Publications Verification
Cat. No.: HY-15186
CAS No.: 1001264-89-6
Purity:  99.79%
Synonyms: GDC-0068; RG7440
Target:  

Organoid Akt Apoptosis

Research Areas:  

Cancer

Ipatasertib (GDC-0068) is an orally active, highly selective and ATP-competitive pan-Akt inhibitor with IC50 values of 5, 18, 8 nM for Akt1/2/3, respectively. Ipatasertib synchronously activates FoxO3a and NF-κB through inhibition of Akt leading to p53-independent activation of PUMA. Ipatasertib also induces apoptosis in cancer cells and inhibits tumor growth in xenograft mouse models .
63
63 Publications Verification
Cat. No.: HY-15186A
CAS No.: 1396257-94-5
Purity:  99.09%
Synonyms: GDC-0068 dihydrochloride; RG-7440 dihydrochloride
Target:  

Organoid Akt

Research Areas:  

Cancer

Ipatasertib dihydrochloride (GDC-0068 dihydrochloride) is a highly selective and ATP-competitive pan-Akt inhibitor with IC50s of 5, 18 and 8 nM for Akt1, Akt2 and Akt3, respectively.
1
1 Cited Publications
Cat. No.: HY-133120
CAS No.: 2503017-97-6
Purity:  99.74%
Target:  

PROTACs Akt

Research Areas:  

Cancer

INY-03-041 is a potent, highly selective and PROTAC-based pan-AKT degrader consisting of the ATP-competitive AKT inhibitor Ipatasertib (HY-15186) conjugated to Lenalidomide (HY-A0003, Cereblon ligand). INY-03-041 inhibits AKT1, AKT2 and AKT3 with IC50s of 2.0, 6.8 and 3.5 nM, respectively .
1
1 Cited Publications
Cat. No.: HY-133120A
Purity:  99.27%
Target:  

PROTACs Akt

Research Areas:  

Cancer

INY-03-041 trihydrochloride is a potent, highly selective and PROTAC-based pan-AKT degrader consisting of the ATP-competitive AKT inhibitor Ipatasertib (HY-15186) conjugated to Lenalidomide (HY-A0003). INY-03-041 trihydrochloride inhibits AKT1, AKT2 and AKT3 with IC50s of 2.0, 6.8 and 3.5 nM, respectively .
Cat. No.: HY-130988
CAS No.: 1001382-14-4
Purity:  99.64%
Synonyms: GDC-0068-NH2; RG7440-NH2
Research Areas:  

Cancer

Ipatasertib-NH2 (GDC-0068-NH2;RG7440-NH2) is a ligand for target protein AKT for PROTAC (INY-03-041). INY-03-041 is composed of Ipatasertib-NH2, a ten-hydrocarbon linker, and a CRBN ligand Lenalidomide for E3 ubiquitin ligase .
Cat. No.: HY-130988A
CAS No.: 1001264-73-8
Synonyms: GDC-0068-NH2 dihydrochloride; RG7440-NH2 dihydrochloride
Research Areas:  

Cancer

Ipatasertib-NH2 dihydrochloride is a ligand for target protein AKT for PROTAC (INY-03-041). INY-03-041 is composed of Ipatasertib-NH2, a ten-hydrocarbon linker, and a CRBN ligand Lenalidomide for E3 ubiquitin ligase .
Cat. No.: HY-15186C
CAS No.: 1491138-24-9
Synonyms: GDC-0068 tosylate; RG7440 tosylate
Target:  

Organoid Akt Apoptosis

Research Areas:  

Cancer

Ipatasertib (GDC-0068) tosylate is an orally active, highly selective and ATP-competitive pan-Akt inhibitor with IC50 values of 5, 18, 8 nM for Akt1/2/3, respectively. Ipatasertib tosylate synchronously activates FoxO3a and NF-κB through inhibition of Akt leading to p53-independent activation of PUMA. Ipatasertib tosylate also induces apoptosis in cancer cells and inhibits tumor growth in xenograft mouse models .
Cat. No.: HY-15947G
CAS No.: 1453848-26-4
Synonyms: GDC-0994 (GMP)
Ravoxertinib GMP is Ravoxertinib (HY-15947) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Ravoxertinib (GDC-0994) is an orally active ERK1/2 inhibitor. Ravoxertinib inhibits the ERK1/2 MAPK signaling pathway and reduces the expression levels of c-Myc, HK2 and LDHA. Ravoxertinib decreases mammosphere formation, and exerts additive and/or superadditive cytotoxicity when combined with Ipatasertib (HY-15186) in 3D tumor sphere models. Ravoxertinib can be used in research related to various cancers including breast cancer, melanoma, head and neck cancer, non-small cell lung cancer, ovarian cancer and Merkel cell carcinoma .